Year All202320222021202020192018201720162015 Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer November 2, 2020 Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19 October 21, 2020 Poseida Therapeutics Added to Membership of US Small-Cap Russell 2000® Index September 18, 2020 Poseida Therapeutics to Present CAR-T Manufacturing Process Optimization Data at CAR-TCR Digital Week 2020 September 16, 2020 Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020 August 20, 2020 Poseida Therapeutics Appoints Harry J. Leonhardt, Esq. as General Counsel July 16, 2020 Poseida Therapeutics Announces Pricing of Initial Public Offering July 9, 2020 Poseida Therapeutics Raises $110 Million in Series D Financing June 25, 2020 Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer May 20, 2020 Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting November 5, 2019
Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer November 2, 2020
Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19 October 21, 2020
Poseida Therapeutics to Present CAR-T Manufacturing Process Optimization Data at CAR-TCR Digital Week 2020 September 16, 2020
Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020 August 20, 2020
Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer May 20, 2020
Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting November 5, 2019
